RBC Capital on Nurix (NRIX): 'Execution in CLL Remains Key'

April 9, 2026 8:34 AM

RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $30.00 price target on Nurix (NASDAQ: NRIX).The analyst commented: "Execution ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found